Spondyloarthritis & psoriatic arthritis
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations
Authors' conclusion
The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.
Study context
- Population
- Patients with PsA and nail psoriasis
- Outcome
- Strength of evidence for nail psoriasis treatments
Methodological detailsGrading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, preformed PICO questions, Search of PubMed, MEDLINE, Embase and Cochrane for evidence since the 2014 GRAPPA nail psoriasis recommendations
- GRADE methodology
- Preformed PICO questions
- Search of PubMed, MEDLINE, Embase and Cochrane for evidence since the 2014 GRAPPA nail psoriasis recommendations
Main finding
As reported in the abstract
- Insufficient evidence to make any recommendation: topical corticosteroids, topical calcipotriol, topical tazarotene, topical cyclosporine, dimethyl fumarates/fumaric acid esters, phototherapy, alitretinoin
- Low strength of evidence supporting: calcipotriol and corticosteroid preparations, topical tacrolimus, oral cyclosporine, oral MTX, intralesional corticosteroids, pulsed dye laser, acitretin, JAKi, apremilast
Original publication
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. Published 1 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →